US protection ending in 2030: Urinary and reproductive
As of the edition of 20 October 2026, 23 drugs have US protection that ends in 2030 in urinary and reproductive; 15 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
23 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Aflibercept | Ends 2030 (orphan exclusivity) | Marketed | Regeneron | PGF, VEGFA | 4 |
| Atrasentan | Ends 2030 (exclusivity) | Marketed | Novartis | EDNRA | 1 |
| Axitinib | Ends 2030 (patent) | Marketed | Pfizer | FLT1, FLT4, KDR | 0 |
| Burosumab | Ends 2030 (computed from the first US licence) | Marketed | Kyowa Kirin | FGF23 | 1 |
| Cemiplimab | Ends 2030 (computed from the first US licence) | Marketed | Regeneron | PDCD1 | 2 |
| Dabrafenib | Ends 2030 (patent) | Marketed | Novartis | BRAF | 1 |
| Erenumab | Ends 2030 (computed from the first US licence) | Marketed | Amgen | CALCRL | 1 |
| Fremanezumab | Ends 2030 (computed from the first US licence) | Marketed | Teva | CALCA, CALCB | 4 |
| Galcanezumab | Ends 2030 (computed from the first US licence) | Marketed | Eli Lilly | CALCA, CALCB | 2 |
| Ibalizumab | Ends 2030 (computed from the first US licence) | Marketed | Theratechnologies | CD4 | 0 |
| Mogamulizumab | Ends 2030 (computed from the first US licence) | Marketed | Kyowa Kirin | CCR4 | 1 |
| Neratinib | Ends 2030 (patent) | Marketed | Puma Biotechnology | EGFR | 2 |
| Omadacycline | Ends 2030 (patent) | Marketed | Transcept Pharmaceuticals | 0 | |
| Pacritinib | Ends 2030 (patent) | Marketed | Swedish Orphan Biovitrum | FLT3, JAK2 | 2 |
| Patiromer sorbitex calcium | Ends 2030 (patent) | Marketed | Sanofi | 0 | |
| Pegvaliase | Ends 2030 (computed from the first US licence) | Marketed | Amicus Therapeutics | 0 | |
| Raltegravir | Ends 2030 (patent) | Marketed | Merck & Co. | 0 | |
| Ravulizumab | Ends 2030 (computed from the first US licence) | Marketed | AstraZeneca | C5 | 0 |
| Sildenafil | Ends 2030 (exclusivity) | Marketed | Viatris | PDE5A | 3 |
| Sotagliflozin | Ends 2030 (patent) | Marketed | Lexicon Pharmaceuticals | SLC5A2 | 2 |
| Tedizolid phosphate | Ends 2030 (patent) | Marketed | Merck & Co. | 0 | |
| Trametinib | Ends 2030 (patent) | Marketed | Novartis | MAP2K1, MAP2K2 | 2 |
| Vemurafenib | Ends 2030 (patent) | Marketed | Roche | BRAF | 1 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2030 in urinary and reproductive
In the product15 of these 23 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.